Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale

on behalf of the AL-108-231 Investigators

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions: Clinically meaningful change is measurable on the PSPRS over 6 months.

Original languageEnglish
Pages (from-to)1574-1577
Number of pages4
JournalMovement Disorders
Issue number10
StatePublished - Oct 1 2016


  • minimal clinically important change (MCIC)
  • progressive supranuclear palsy (PSP)
  • progressive supranuclear palsy rating scale (PSPRS)


Dive into the research topics of 'Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale'. Together they form a unique fingerprint.

Cite this